文献速递垂体与肾上腺疾病

Tildacerfont治疗成人经典型先天性肾上腺皮质增生症:两项2期研究结果

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

两项2期开放标签研究评估了口服Tildacerfont在21羟化酶缺陷症成人患者中的安全性和有效性。研究显示,基线A4>2倍正常上限的患者中,ACTH、17-OHP和A4均较基线下降;基线A4≤2倍正常上限的患者生物标志物维持稳定。总体不良事件发生率为53.6%。

要点

  • 基线A4>2×ULN者,Tildacerfont可降低ACTH、17-OHP和A4水平。
  • 基线A4≤2×ULN者,治疗期间生物标志物水平维持稳定。
  • 总体不良事件发生率53.6%,常见头痛和上呼吸道感染。

核心结论

  • 对于21OHD患者,口服Tildacerfont最长12周可使关键激素生物标志物降低或维持在接近正常水平。

研究设计与样本

  • 两项2期开放标签研究,纳入成人21OHD患者;研究1中口服Tildacerfont 200-1000 mg每日一次(n=10)或100-200 mg每日两次(n=9和7)治疗2周;研究2中口服400 mg每日一次(n=11)治疗12周。

主要发现

  • 研究1中基线A4>2×ULN可评估患者(n=11;19-67岁,55%女性)ACTH较基线降低59.4%至28.4%,17-OHP降低38.3%至0.3%,A4降低24.2%至18.1%,未见明确剂量反应。
  • 研究2中基线A4>2×ULN患者(n=5;26-63岁,40%女性)生物标志物水平最大平均降低约80%,ACTH和A4分别有60%和40%恢复正常。
  • 两项研究中基线A4≤2×ULN的患者生物标志物水平维持稳定。
  • 总体不良事件发生率53.6%,包括头痛(7.1%)和上呼吸道感染(7.1%)。

临床怎么用

  • Tildacerfont可能作为21OHD患者减少糖皮质激素用量的辅助治疗,但需进一步研究确认。

局限性

  • 研究为开放标签设计,样本量小,部分亚组样本量更小,缺乏对照,随访时间最长12周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treated with lifelong supraphysiologic doses of glucocorticoids (GCs). Tildacerfont, a corticotropin-releasing factor type-1 receptor antagonist, may reduce excess androgen production, allowing for GC dose reduction. OBJECTIVE: Assess tildacerfont safety and efficacy. DESIGN AND SETTING: Two Phase 2 open-label studies. PATIENTS: Adults with 21OHD. INTERVENTION: Oral tildacerfont 200 to 1000 mg once daily (QD) (n = 10) or 100 to 200 mg twice daily (n = 9 and 7) for 2 weeks (Study 1), and 400 mg QD (n = 11) for 12 weeks (Study 2). MAIN OUTCOME MEASURE: Efficacy was evaluated by changes from baseline at 8 am in adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), and androstenedione (A4) according to baseline A4 ≤ 2× upper limit of normal (ULN) or A4 > 2× ULN. Safety was evaluated using adverse events (AEs) and laboratory assessments. RESULTS: In Study 1, evaluable participants with baseline A4 > 2× ULN (n = 11; 19-67 years, 55% female) had reductions from baseline in ACTH (-59.4% to -28.4%), 17-OHP (-38.3% to 0.3%), and A4 (-24.2% to -18.1%), with no clear dose response. In Study 2, participants with baseline A4 > 2× ULN (n = 5; 26-63 years, 40% female) had ~80% maximum mean reductions in biomarker levels. ACTH and A4 were normalized for 60% and 40%, respectively. In both studies, participants with baseline A4 ≤ 2× ULN maintained biomarker levels. AEs (in 53.6% of patients overall) included headache (7.1%) and upper respiratory tract infection (7.1%). CONCLUSIONS: For patients with 21OHD, up to 12 weeks of oral tildacerfont reduced or maintained key hormone biomarkers toward normal.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sarafoglou K, Barnes CN, Huang M, et al. Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. J Clin Endocrinol Metab. 2021. PMID: 34146101. doi:10.1210/clinem/dgab438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。